
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
wacomka Deals and Financings In a blockbuster agreement, Guangzhou’s Akeso (OTCPK:AKESF) out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion (see story). Summit Therapeutics (SMMT) of Menlo Park, […]